0.8181 -0.039 (-4.52%) | 04-26 16:00 | |||||||||||||
|
|
Short term | ||||
Mid term | ||||
Targets | 6-month : | 1.17 | 1-year : | 1.31 |
Resists | First : | 1 | Second : | 1.12 |
Pivot price | 0.93 | |||
Supports | First : | 0.8 | Second : | 0.66 |
MAs | MA(5) : | 0.86 | MA(20) : | 0.97 |
MA(100) : | 1.03 | MA(250) : | 2.56 | |
MACD | MACD : | -0.1 | Signal : | -0.1 |
%K %D | K(14,3) : | 11.7 | D(3) : | 9.7 |
RSI | RSI(14): 32.8 | |||
52-week | High : | 6 | Low : | 0.8 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ MYNZ ] has closed above bottom band by 7.9%. Bollinger Bands are 7.1% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
If tomorrow: | Open lower | Open higher |
High: | 0.88 - 0.89 | 0.89 - 0.89 |
Low: | 0.79 - 0.79 | 0.79 - 0.8 |
Close: | 0.81 - 0.82 | 0.82 - 0.83 |
Mainz Biomed B.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics in human genetics. It offers ColoAlert, a colorectal cancer screening test; PancAlert, a product candidate for a pancreatic cancer screening test; GenoStrip to detect pathogens in environments on a molecular genetic basis; and research-use-only and IVD tests. The company was founded in 2008 and is based in Mainz, Germany.
Wed, 24 Apr 2024
Mainz Biomed Announces Upcoming Annual Meeting - TipRanks.com - TipRanks
Fri, 19 Apr 2024
Mainz Biomed Secures New Funding Agreement - TipRanks.com - TipRanks
Wed, 10 Apr 2024
Mainz Biomed B.V. Confronts Escalating Cybersecurity Dangers Threatening Operations and Data Security - TipRanks ... - TipRanks
Tue, 05 Dec 2023
Mainz Biomed stock falls on U.S. trial data for cancer test - Seeking Alpha
Wed, 26 Jan 2022
Why Mainz Biomed Stock Is Crashing Today - The Motley Fool
Fri, 21 Jan 2022
Mainz Biomed BV (MYNZ) Stock Gains 49.94% This Week: Is It a Good Pick? - InvestorsObserver
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
Exchange:
NASDAQ
|
|
Sector:
Healthcare
|
|
Industry:
Medical - Diagnostics & Research
|
|
Shares Out | 0 (M) |
Shares Float | 22 (M) |
Held by Insiders | 1.839e+007 (%) |
Held by Institutions | 16.5 (%) |
Shares Short | 347 (K) |
Shares Short P.Month | 0 (K) |
EPS | -2.607e+007 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 0 |
Profit Margin | 0 % |
Operating Margin | -3 % |
Return on Assets (ttm) | 68.7 % |
Return on Equity (ttm) | -93.5 % |
Qtrly Rev. Growth | 895480 % |
Gross Profit (p.s.) | 46.25 |
Sales Per Share | -1263.34 |
EBITDA (p.s.) | 0 |
Qtrly Earnings Growth | -1.7 % |
Operating Cash Flow | 0 (M) |
Levered Free Cash Flow | -22 (M) |
PE Ratio | -0.01 |
PEG Ratio | 0 |
Price to Book value | 0 |
Price to Sales | -0.01 |
Price to Cash Flow | 1.3 |
Dividend | 0 |
Forward Dividend | 307280 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |